AbbVie(ABBV) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - AbbVie reported full-year adjusted earnings per share of $10, exceeding initial guidance by $0.54, and total net revenues of $61.2 billion, surpassing guidance by over $2 billion [4][5] - Sales growth of 8.6% led to record net sales, exceeding previous peak revenue by more than $3 billion despite nearly $16 billion erosion from U.S. Humira [5][6] - Adjusted earnings per share for Q4 were $2.71, $0.08 above guidance midpoint, with total net revenues of $16.6 billion reflecting robust growth of 10% [33][34] Business Line Data and Key Metrics Changes - Immunology revenues reached approximately $8.6 billion in Q4, with Skyrizi sales of $5 billion (31.9% operational growth) and Rinvoq sales of nearly $2.4 billion (28.6% operational growth) [10][11] - Neuroscience full-year revenues exceeded $10.7 billion, with Q4 revenues of over $2.9 billion (17.3% operational growth), driven by Vraylar and Botox Therapeutic [17][18] - Oncology revenues were nearly $1.7 billion in Q4, down 2.5% operationally, with Venclexta sales of $710 million (6.4% operational growth) [19][20] Market Data and Key Metrics Changes - Global sales for Skyrizi in IBD reached approximately $6.4 billion in 2025, more than double the prior year's performance [13] - Humira delivered global sales of over $1.2 billion, down 26.1% operationally due to biosimilar competition [17] - The aesthetics segment saw global sales of nearly $1.3 billion in Q4, down 1.2% operationally, with Botox Cosmetic revenues of $717 million (3.8% operational growth) [20][21] Company Strategy and Development Direction - AbbVie plans to deliver total sales growth of 9.5% in 2026, driven by Skyrizi and Rinvoq, with combined sales expected to exceed $31 billion [6][7] - The company is focused on advancing its pipeline with significant investments in R&D, including over $5 billion in new business development [5][6] - A voluntary agreement with the U.S. government aims to enhance patient access and affordability while committing $100 billion in U.S. R&D and capital investments over the next decade [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in AbbVie's strong position to deliver high single-digit revenue growth through 2029, despite headwinds from Humira erosion and Imbruvica pricing [6][9] - The company anticipates key catalysts in R&D across immunology, neuroscience, and oncology over the next 24 months [8][9] - Management highlighted the potential for sustained long-term growth driven by innovative therapies and strategic acquisitions [9][10] Other Important Information - AbbVie increased adjusted R&D expense by nearly $1 billion in 2025, fully funding 90 clinical programs currently in development [5][6] - The company expects to generate free cash flow of approximately $18.5 billion in 2026, supporting a strong and growing quarterly dividend [39][40] Q&A Session Summary Question: Details on the psychedelic therapy in development - Management highlighted the potential of the psychedelic therapy to provide immediate efficacy with a short-acting profile, aiming for a breakthrough in treatment [41][42] Question: Insights on Skyrizi in IBD and market expectations - Management confirmed stable new patient starts for Skyrizi in both Crohn's and UC, with high capture rates despite competition [44][46] - They expressed confidence in the long-term growth potential for Skyrizi and Rinvoq, indicating that current market models may not fully reflect this upside [48][49] Question: Update on external innovation and business development - AbbVie has invested over $8 billion in external innovation, focusing on early-stage opportunities to drive growth in immunology, neuroscience, and oncology [52][54] Question: Expectations for Rinvoq and Lutikizumab phase 3 data - Management emphasized the importance of upcoming studies for Rinvoq and Lutikizumab, particularly in treatment failure populations, and expressed optimism based on previous performance [55][56]